Will Bioniche Life Sciences’ activist shareholders unlock value?

A group of dissident shareholders led by former Biovail CEO Bill Wells openly wonders why Bioniche CEO Graeme Mcrae is still at the helm of the struggling company.

This morning, a dissident group of shareholders of Bioniche Life Sciences (TSX:BNC), led by former Biovail CEO Bill Wells, wrote an open letter to Bioniche Chairman James Rae. The letter, authored by Wells and Greg Gubitz, former General Counsel and Senior Vice President of Corporate Development at Biovail, points out that despite a share price [...]

Bioniche cancels Urocidin trial, stock falls hard

Bioniche said the study was not being recruited at the expected rate, and after recent discussions with the US FDA regarding the trial design, Endo has decided to end the study prior to completion.

Shares of Bioniche Life Sciences (TSX:BNC) plummeted Monday after the biopharmaceutical company said that it is discontinuing a second phase III trial with Urocidin – a potential treatment for a type of bladder cancer. The randomized, open-label, multi-centre study was being run by the company’s global licensing partner – Endo Pharmaceuticals – a subsidiary of [...]

The $3 Solution to E. Coli outbreaks the Canadian Government is ignoring

Bioniche CEO McRae: "Essentially, Econiche is a public health vaccine that is administered to cattle."

Last Thursday, Alberta beef processor XL Foods issued a statement acknowledging that, in the wake of a massive recall of beef products after an outbreak of a strain of E. coli virus, its food safety practices were lacking. The statement, which came more than three weeks after the incident occurred, has many calling for the [...]

Bioniche Belt-Tightening Paying Off for Shareholders

Monique Champagne, Bioniche Life Sciences VP, Clinical Research and Graeme McRae, the company's CEO accept an Accolades 2011 Award of Excellence for High Technology and Innovation from The West Island of Montreal Chamber of Commerce on May 26, 2011.

A cursory glance at a three-year chart of Belleville’s Bioniche Life Sciences (TSX:BNC) illustrates the promise and subsequent disappointment of the company’s plans to expand beyond its core business. A closer look reveals a minor resurgence is underway, as the company has focused on the bottom line during the transition. For years, Bioniche was better [...]

Cantech Awards: The Numbers

Karsan: "Glentel's stock performance illustrates how value investors can profit from such companies in two ways: earnings growth, and multiple expansion. When these two forces combine, as they did with Glentel over the past year, returns for investors can be phenomenal"

The voting for 2010 Canadian Tech Stock of the Year contained some obvious choices. SXC Health, for instance, added a billion dollars in market value and posted a 40% top line gain. Westport Innovation’s stock continued a dramatic run that began in 2009. In 2010 it was also revealed that legendary investor George Soros became [...]

The 100% Club: 15 TSX Techs that Doubled in 2010

The Mad Catz Street Fighter IV FightStick for XBox

Another year, and another year of mining stock successes on the Toronto Stock Exchange. It seems like decades since a technology stock really made a difference to the index, and 2010 was not the year to break that pattern. In fact, only one technology related issue cracked the top thirty five performing stocks on the [...]

The 2010 Cantech Letter Awards: The Nominees

Mark Therier, President and CEO of SXC Health

When we decided to hold the first ever Cantech Letter Awards we were immediately faced with some tough choices. How many categories should there be? Which companies should be eligible? Should we simply take the ten best performing stocks and let our readers vote on them? What about revenue growth, is that more important than share price? Perhaps a combination of the two? Should a percentage gain in either be weighted more heavily to larger stocks? In the end we decided on two categories: Canadian Technology Stock of the Year and Canadian Technology Executive of the Year. We also invited a panel of judges to help us to not only choose the winners, but also the candidates…

Cantech Letter interviews Industry Minister Tony Clement

Clement: "Canada’s long-term economic well-being depends, as never before, on ideas, innovation and inventiveness."

It’s been nearly a century since Canada’s greatest achievement in biotech took place; the discovery of insulin by Frederick Banting and his assistant Charles Best, in 1922. While nothing since has matched that miraculous feat, which has saved countless millions of lives, it’s not like Canada has been sitting still in the meantime. Canadian researchers have contributed to The Human Genome project, cracked the genetic code of the mosquito that carries the deadliest strain of malaria, and deciphered human chromosome 7, which holds the gene for cystic fibrosis. Our December issue is about Canadian Life Sciences stocks carrying the torch of innovation.

10 Canadian Life Sciences Stocks that could Change the World

Immunovaccine's Chase: "We haven’t found a vaccine yet that we cannot improve."

It’s been nearly a century since Canada’s greatest achievement in biotech took place; the discovery of insulin by Frederick Banting and his assistant Charles Best, in 1922. While nothing since has matched that miraculous feat, which has saved countless millions of lives, it’s not like Canada has been sitting still in the meantime. Canadian researchers [...]

Bioniche Life Sciences rallies around milestone payments

Graeme McRae, President and CEO of Bioniche Life Sciences (TSX:BNC)

For years, Belleville, Ontario’s Bioniche Life Sciences (TSX:BNC) was better known to your veterinarian than your doctor. Bioniche, which formed in 1979 to develop veterinary bio pharmaceutical products, received worldwide attention two years ago when it received a Canadian license for Econiche, the world’s first cattle vaccine against E. coli. Sales of Bioniche veterinary products [...]